| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Morantel tartrate acts as a cholinergic agonist at nicotinic acetylcholine receptors on nematode muscle cells. By binding to these receptors, it causes sustained depolarization and spastic paralysis of the worms, leading to their expulsion from the host. This mechanism is shared with other tetrahydropyrimidine anthelmintics such as pyrantel. The compound's selectivity for nematode over mammalian receptors contributes to its low toxicity profile.
|
|---|---|
| ln Vitro |
In vitro, Morantel tartrate demonstrates broad-spectrum anthelmintic activity against various nematode species. It is effective against both immature and adult stages of certain nematodes. Detailed in vitro activity data, including specific IC50 values against different nematode species, are not extensively reported in the available literature. Its activity is confirmed through standard in vitro motility assays using nematode larvae or adult worms.
|
| ln Vivo |
In vivo, Morantel tartrate is effective against gastrointestinal nematode infections in livestock. It is used for the removal of parasitic worms in livestock. The compound is well-tolerated and has a high efficacy and low toxicity profile. It is administered orally to animals. Detailed in vivo efficacy data from specific animal studies are not extensively reported in the available literature.
|
| Enzyme Assay |
Non-cell-based assays for Morantel tartrate are not typical, as its mechanism involves binding to nicotinic acetylcholine receptors on nematode muscle cells. Receptor binding studies may be performed using membrane preparations from nematode tissue or from cells expressing nematode nicotinic receptors. The compound is incubated with a radiolabeled nicotinic receptor ligand, and binding affinity is determined by measuring displacement of the radiolabeled ligand.
|
| Cell Assay |
Cellular assays for Morantel tartrate utilize nematode muscle cells or whole worms to assess anthelmintic activity. Nematode larvae or adult worms are incubated with the compound at various concentrations in liquid medium. Worm motility is assessed visually or using automated systems to determine the concentration that causes paralysis or death. EC50 values for inhibition of motility are determined from dose-response curves.
|
| Animal Protocol |
In vivo animal models for Morantel tartrate involve livestock (cattle, sheep, goats, pigs, horses) naturally or experimentally infected with gastrointestinal nematodes. The compound is administered orally at recommended doses. Efficacy is assessed by measuring fecal egg count reduction (FECR) before and after treatment. The compound's efficacy against various nematode species is determined by identifying and counting worm burdens at necropsy. Detailed protocols are not extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Morantel tartrate include a molecular weight of 370.42 g/mol and molecular formula C16H22N2O6S. CAS number is 26155-31-7. Purity is >98%. Appearance is white to off-white crystalline powder. Melting point is 164-168°C. Solubility: soluble in water. Shelf life is 2 years; storage at -20°C. Detailed PK parameters such as half-life and bioavailability are not extensively reported.
|
| Toxicity/Toxicokinetics |
Morantel tartrate is a low-toxicity broad-spectrum anthelmintic. It is well-tolerated in livestock. Detailed toxicological data are not extensively reported, but its safety profile is well-established from veterinary use. The compound is for veterinary use and is not for human consumption. Standard toxicity assessments would evaluate effects on gastrointestinal, hepatic, and renal function.
|
| Additional Infomation |
Primarily used as an anti-nematode drug for livestock.
See also: Morantel (contains active ingredient). Morantel tartrate is cataloged under CAS number 26155-31-7. It is a low-toxicity, broad-spectrum anthelmintic that is the 3-methyl thiophene tartrate salt analog of pyrantel tartrate. It is effective against immature and adult stages of certain nematodes. It is used primarily in veterinary medicine for livestock. It has a molecular weight of 370.42 g/mol and is a tetrahydropyrimidine compound. It is well-tolerated and has high efficacy and low toxicity. |
| Molecular Formula |
C12H16N2S.C4H6O6
|
|---|---|
| Molecular Weight |
370.42068
|
| Exact Mass |
370.119
|
| CAS # |
26155-31-7
|
| Related CAS # |
20574-50-9;26155-31-7 (tartrate);
|
| PubChem CID |
6433951
|
| Appearance |
Off-white to light yellow solid powder
|
| Boiling Point |
334.6ºC at 760 mmHg
|
| Flash Point |
156.1ºC
|
| Vapour Pressure |
0.000127mmHg at 25°C
|
| LogP |
0.054
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
407
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C(/C=C/C2=NCCCN2C)SC=C1.O=C(O)[C@H](O)[C@@H](O)C(O)=O
|
| InChi Key |
GGXQONWGCAQGNA-UUSVNAAPSA-N
|
| InChi Code |
InChI=1S/C12H16N2S.C4H6O6/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2;5-1(3(7)8)2(6)4(9)10/h4-6,9H,3,7-8H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/b5-4+;/t;1-,2-/m.1/s1
|
| Chemical Name |
(2R,3R)-2,3-dihydroxybutanedioic acid;1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~337.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6996 mL | 13.4982 mL | 26.9964 mL | |
| 5 mM | 0.5399 mL | 2.6996 mL | 5.3993 mL | |
| 10 mM | 0.2700 mL | 1.3498 mL | 2.6996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
